SCHEMBL6458038

SCHEMBL6458038

CCOC(=O)COc1ccc(F)c(Cl)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 3/20 0.53
GAA P10253 3/20 0.53
KDM4E B2RXH2 2/20 0.53
MAPT P10636 4/20 0.53
MAPK1 P28482 3/20 0.53
NPC1 O15118 1/20 0.53
NPSR1 Q6W5P4 2/20 0.52
HPGD P15428 3/20 0.49
LMNA P02545 2/20 0.48
POLB P06746 1/20 0.48
PPARG P37231 1/20 0.47
PPARA Q07869 1/20 0.47
MCL1 Q07820 1/20 0.47
ALDH1A1 P00352 3/20 0.46
CYP1A2 P05177 2/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2C19 P33261 2/20 0.46
CYP2C9 P11712 1/20 0.46
NTSR1 P30989 1/20 0.46
TP53 P04637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL903866 0.88 GAA (0.53) HSD17B10GAAKDM4EMAPTMAPK1
SCHEMBL903954 0.86 GAA (0.57) HSD17B10GAAKDM4EMAPTMAPK1
SCHEMBL17973238 0.86 KDM4E (0.57) HSD17B10GAAKDM4EMAPTMAPK1
SCHEMBL13744660 0.85 GAA (0.56) HSD17B10GAAKDM4EMAPTMAPK1
SCHEMBL1257644 0.85 KDM4E (0.56) HSD17B10GAAKDM4EMAPTMAPK1
SCHEMBL16566924 0.84 GAA (0.55) HSD17B10GAAKDM4EMAPTMAPK1
SCHEMBL7486777 0.84 HPGD (0.56) HSD17B10GAAKDM4EMAPTMAPK1
SCHEMBL5531605 0.82 GAA (0.53) HSD17B10GAAKDM4EMAPTMAPK1
SCHEMBL8251631 0.82 GAA (0.56) HSD17B10GAAKDM4EMAPTMAPK1
SCHEMBL17973242 0.82 MCL1 (0.69) HSD17B10GAAKDM4ENPC1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160237059-A1 HETEROCYCLIC SUBSTITUTED TRIFLUOROMETHYL PYRIMIDINONES AND THEIR USE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-08-18 US disclosed
US-20160237059-A1 HETEROCYCLIC SUBSTITUTED TRIFLUOROMETHYL PYRIMIDINONES AND THEIR USE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-08-18 US disclosed
US-20160221965-A1 DISUBSTITUTED TRIFLUOROMETHYL PYRIMIDINONES AND THEIR USE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-08-04 US disclosed
US-20160221965-A1 DISUBSTITUTED TRIFLUOROMETHYL PYRIMIDINONES AND THEIR USE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-08-04 US disclosed
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO., LTD. 2005-09-08 US disclosed
WO-2004087669-A1 NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMACEUTICAL CO. LTD. (JP) 2004-10-14 WO disclosed
EP-1464335-A2 Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist Taisho Pharmaceutical Co. Ltd. (JP) 2004-10-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160221965-A1 DISUBSTITUTED TRIFLUOROMETHYL PYRIMIDINONES AND THEIR USE REN, GLS, FIBP HSD17B10 4370/4885GAA 1316/4885KDM4E 2697/4885
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof HCRTR2, MCHR1, MCHR2 HSD17B10 2130/4885GAA 484/4885KDM4E 1190/4885
US-20160237059-A1 HETEROCYCLIC SUBSTITUTED TRIFLUOROMETHYL PYRIMIDINONES AND THEIR USE REN, GLS, FIBP HSD17B10 4092/4885GAA 1210/4885KDM4E 2692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.